



Living Cell Technologies Limited Company Announcement

LCT completes pre-clinical studies of NTCELL in Parkinson's

28 February 2012 – Sydney, Australia and Auckland, New Zealand – Living Cell Technologies Limited (ASX: LCT; OTCQX: LVCLY) today announced the successful completion of pre-clinical studies for NTCELL, a potential innovative treatment for Parkinson's disease.

Based on the promising results, the company is compiling an application to New Zealand's medicines safety authority, Medsafe, to start Phase I clinical trials in Parkinson's patients. Pending regulatory authorisation, Living Cell Technologies expects to begin these trials by the end of Q1 2013.

In the controlled trial a Parkinson's-like condition was produced in non-human primates using drugs which selectively deplete dopamine producing neurons in the brain. Reduction of dopamine levels in the brain is a hallmark of Parkinson's disease in humans. The non-human primates developed movement disorders and neurological deficits similar to Parkinson's patients. NTCELL was then implanted into the affected brain areas and within two weeks, improvements in both motor abnormalities and neurological function were observed in the NTCELL treated subjects compared to controls. These improvements increased and persisted for at least six months beyond the NTCELL implant, the end-point of the study. Microscopic analysis of both treated and untreated brain regions clearly showed an increase in the number of dopamine producing neurons in the NTCELL treated subjects compared to controls. In addition, there was no cellular or pathological evidence of inflammation or other adverse event.

These results are consistent with all Living Cell Technologies' prior pre-clinical NTCELL studies in other small animal models of Parkinson's.

"Concluding our pre-clinical studies is an important step in developing our next therapeutic product beyond DIABECCELL[®]," says Dr Andrea Grant, CEO, Living Cell Technologies. "These results show an astonishing recovery of the affected part of the brain, demonstrating NTCELL's promising efficacy in the treatment of late stage Parkinson's disease. If these results translate into human studies, then a major new treatment would result."

LCT's approach is unique from others which have attempted cell transplant treatments for Parkinson's. Rather than transplanting adult neurons or embryonic stem cells, LCT is using a naturally occurring support cell to induce appropriate regeneration from the neurons already present in the subjects' brains.

"It seems we are prompting the brain's own biology to heal itself," said Professor Bob Elliott, Medical Director, Living Cell Technology. "By also enclosing these cells in our proprietary encapsulation technology IMMUPEL[™], we protect against adverse immune reaction and ensure the cells continue to survive in the treated area and continue to deliver their beneficial effect."

About Living Cell Technologies

Living Cell Technologies (LCT) is developing cell-based products to treat life threatening human diseases. The Company holds 50% of Diatranz Otsuka Limited which owns a bio-

certified pig herd that it uses as a source of cells and DIABECCELL® which is designed to help normalise the lives of people with unstable Type 1 diabetes, especially those suffering from life-threatening episodes of unaware hypoglycaemia (low blood sugar), a dangerous and potentially fatal diabetes complication. Using breakthrough proprietary microencapsulation technology, IMMUPEL™, which enables implantation of cell-based therapeutics without immunosuppression, LCT is developing NTCELL, a choroid plexus cell product which is currently in preclinical development to treat neurodegenerative diseases such as Parkinson's disease, Huntington's disease, stroke, and hearing loss. LCT also offers medical-grade porcine-derived products for the repair and replacement of damaged tissues, as well as for research and other purposes.

For further information: www.lctglobal.com

At the company: Andrea Grant, Chief Executive Tel: +64 9 276 2690 Mobile: +64 21 0785 421 agrant@lctglobal.com	Media and investor enquiries: Sally Raudon Botica Butler Raudon Partners Tel: +64 9 303 3862 Mobile: +64 21 402 502 sallyr@botica.co.nz
---	--

LCT Disclaimer

This document contains certain forward-looking statements, relating to LCT's business, which can be identified by the use of forward-looking terminology such as "promising," "plans," "anticipated," "will," "project," "believe," "forecast," "expected," "estimated," "targeting," "aiming," "set to," "potential," "seeking to," "goal," "could provide," "intends," "is being developed," "could be," "on track," or similar expressions, or by express or implied discussions regarding potential filings or marketing approvals, or potential future sales of product candidates. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause actual results to be materially different from any future results, performance or achievements expressed or implied by such statements. There can be no assurance that any existing or future regulatory filings will satisfy the FDA's and other health authorities' requirements regarding any one or more product candidates nor can there be any assurance that such product candidates will be approved by any health authorities for sale in any market or that they will reach any particular level of sales. In particular, management's expectations regarding the approval and commercialization of the product candidates could be affected by, among other things, unexpected clinical trial results, including additional analysis of existing clinical data, and new clinical data; unexpected regulatory actions or delays, or government regulation generally; our ability to obtain or maintain patent or other proprietary intellectual property protection; competition in general; government, industry, and general public pricing pressures; and additional factors that involve significant risks and uncertainties about our products, product candidates, financial results and business prospects. Should one or more of these risks or uncertainties materialize, or should underlying assumptions prove incorrect, actual results may vary materially from those described herein as anticipated, believed, estimated or expected. LCT is providing this information and does not assume any obligation to update any forward-looking statements contained in this document as a result of new information, future events or developments or otherwise.